«123456»Seite
6 Artikel mit Literatur, Seite 3 von 6

MEDIZIN: Übersichtsarbeit

Diagnostik und Therapie der minimalen hepatischen Enzephalopathie

The Diagnosis and Treatment of Minimal Hepatic Encephalopathy
Dtsch Arztebl Int 2012; 109(10): 180-7; DOI: 10.3238/arztebl.2012.0180

Zhan, Tianzuo; Stremmel, Wolfgang

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT: Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716–21 CrossRef MEDLINE
2. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H: Neuropsychological characterization of hepatic encephalopathy.
J Hepatol 2001; 34: 768–73 CrossRef MEDLINE
3. Schomerus H, Hamster W: Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16: 37–41 CrossRef MEDLINE
4. Groeneweg M, Quero JC, De Bruijn I, et al.: Subclinical hepatic
encephalopathy impairs daily functioning. Hepatology 1998; 28: 45–9 CrossRef MEDLINE
5. Roman E, Cordoba J, Torrens M, et al.: Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol 2011; 106: 476–82 CrossRef MEDLINE
6. Bajaj JS, Saeian K, Schubert CM, et al.: Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50: 1175–83 CrossRef MEDLINE PubMed Central
7. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J: Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718–23 MEDLINE
8. Amodio P, Del Piccolo F, Marchetti P, et al.: Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999; 29: 1662–7 CrossRef MEDLINE
9. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R: Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549–59 CrossRef MEDLINE
10. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK: Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307–16 CrossRef MEDLINE
11. Bajaj JS, Heuman DM, Wade JB, et al.: Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478–87 CrossRef MEDLINE PubMed Central
12. Lockwood AH, Yap EW, Wong WH: Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337–41 CrossRef MEDLINE
13. Shawcross DL, Wright G, Olde Damink SW, Jalan R: Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007; 22: 125–38 CrossRef MEDLINE
14. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM: Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441–9 CrossRef MEDLINE
15. Ong JP, Aggarwal A, Krieger D, et al.: Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188–93 CrossRef MEDLINE
16. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D: Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35: 357–66 CrossRef MEDLINE
17. Lockwood AH, Weissenborn K, Bokemeyer M, Tietge U, Burchert W: Correlations between cerebral glucose metabolism and neuropsychological test performance in nonalcoholic cirrhotics. Metab Brain Dis 2002; 17: 29–40 CrossRef MEDLINE
18. Blei AT, Cordoba J: Hepatic Encephalopathy. Am J Gastroenterol 2001; 96: 1968–76 CrossRef MEDLINE
19. Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB: Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000; 45: 1549–52 CrossRef MEDLINE
20. Watanabe A, Sakai T, Sato S, et al.: Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410–4 CrossRef MEDLINE
21. Sharma BC, Sharma P, Agrawal A, Sarin SK: Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled
trial of lactulose versus placebo. Gastroenterology 2009; 137: 885–91 CrossRef MEDLINE
22. Bass NM, Mullen KD, Sanyal A, et al.: Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071–81 CrossRef MEDLINE
23. Plauth M, Cabre E, Riggio O, et al.: ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25: 285–94 CrossRef MEDLINE
24. Malaguarnera M, Gargante MP, Cristaldi E, et al.: Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 2008; 53: 3018–25 CrossRef MEDLINE
25. Bajaj JS, Saeian K, Christensen KM, et al.: Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707–15.
CrossRef MEDLINE
e1. Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R, et al.: Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol 2010; 25: 1029–41 MEDLINE
e2. Sharma P, Sharma BC, Puri V, Sarin SK: Minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Am J Gastroenterol 2008; 103: 1406–12 MEDLINE
e3. Sarin SK, Nundy S: Subclinical encephalopathy after portosystemic shunts in patients with non-cirrhotic portal fibrosis. Liver 1985; 5: 142–6 MEDLINE
e4. Bajaj JS, Etemadian A, Hafeezullah M, Saeian K: Testing for minimal hepatic encephalopathy in the United States: An AASLD survey. Hepatology 2007; 45: 833–4 CrossRef MEDLINE
e5. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K: Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007; 102: 1903–9 CrossRef MEDLINE
e6. Bajaj JS, Hafeezullah M, Hoffmann RG, Varma RR, Franco J, Binion DG, et al.: Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008; 47: 596–604 MEDLINE
e7. Bajaj JS, Hafeezullah M, Zadvornova Y, Martin E, Schubert CM, Gibson DP, et al.: The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol 2009; 104: 898–905 MEDLINE
e8. Bajaj JS, Saeian K, Hafeezullah M, Hoffmann RG, Hammeke TA: Patients with minimal hepatic encephalopathy have poor insight into their driving skills. Clin Gastroenterol Hepatol 2008; 6: 1135–9; quiz 1065 CrossRef MEDLINE
e9. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR: Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531–5 MEDLINE
e10. Dhiman RK, Kurmi R, Thumburu KK, Venkataramarao SH, Agarwal R, Duseja A, et al.: Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010; 55: 2381–90 MEDLINE
e11. Cooper AJ, Plum F: Biochemistry and physiology of brain ammonia. Physiol Rev 1987; 67: 440–519 MEDLINE
e12. Cordoba J, Alonso J, Rovira A, Jacas C, Sanpedro F, Castells L, et al.: The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001; 35: 598–604 MEDLINE
e13. Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, et al.: Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999; 117: 640–4 MEDLINE
e14. Ahboucha S, Butterworth RF: The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. Neurochem Int 2008; 52: 575–87 CrossRef MEDLINE
e15. Cagnin A, Taylor-Robinson SD, Forton DM, Banati RB: In vivo imaging of cerebral „peripheral benzodiazepine binding sites“ in patients with hepatic encephalopathy. Gut 2006; 55: 547–53 MEDLINE PubMed Central
e16. Folstein MF, Folstein SE, McHugh PR: „Mini-mental state“. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98 MEDLINE
e17. Romero-Gomez M, Cordoba J, Jover R, del Olmo JA, Ramirez M, Rey R, et al.: Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007; 45: 879–85 MEDLINE
e18. Amodio P, Marchetti P, Del Piccolo F, de Tourtchaninoff M, Varghese P, Zuliani C, et al.: Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 1999; 110: 1334–44 MEDLINE
e19. Saxena N, Bhatia M, Joshi YK, Garg PK, Tandon RK: Auditory P300 event-related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study. J Gastroenterol Hepatol 2001; 16: 322–7 CrossRef MEDLINE
e20. Weissenborn K, Ehrenheim C, Hori A, Kubicka S, Manns MP: Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation. Metab Brain Dis 1995; 10: 219–31 MEDLINE
e21. Naegele T, Grodd W, Viebahn R, Seeger U, Klose U, Seitz D, et al.: MR imaging and (1)H spectroscopy of brain metabolites in hepatic encephalopathy: time-course of renormalization after liver transplantation. Radiology 2000; 216: 683–91 MEDLINE
e22. Kale RA, Gupta RK, Saraswat VA, Hasan KM, Trivedi R, Mishra AM, et al.: Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 2006; 43: 698–706 MEDLINE
e23. Trzepacz PT, Tarter RE, Shah A, Tringali R, Faett DG, Van Thiel DH: SPECT scan and cognitive findings in subclinical hepatic encephalopathy. J Neuropsychiatry Clin Neurosci 1994; 6: 170–5 MEDLINE
e24.Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM: Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010; 31: 1012–7 MEDLINE
e25. van Leeuwen PA, van Berlo CL, Soeters PB : New mode of action for lactulose. Lancet 1988; 1: 55–6 MEDLINE
e26. Als-Nielsen B, Gluud LL, Gluud C: Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046 CrossRef MEDLINE PubMed Central
e27. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al.: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573–83 MEDLINE
e28. Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, et al.: Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 2011; 106: 1081–8 MEDLINE
e29. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Gortelmeyer R, et al.: Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998; 28: 856–64 MEDLINE
e30. Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, et al.: Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 2008; 53: 3018–25 MEDLINE
e31. Tuerk MJ, Fazel N: Zinc deficiency. Curr Opin Gastroenterol 2009; 25: 136–43 CrossRef
e32. Conn HO, Bircher J: Quantifying the severity of hepatic encephalopathy: syndromes and therapies. In: Conn HO, Bircher J (eds.) Hepatic encephalopathy: syndromes and therapies. East Lansing MI: Medi Ed Press. 1993: 13–26.
e33.Spezialambulanz für Gedächtnisstörungen am AKH Wien. (Internet). Vienna: Department of Neurology, Medical Faculty of Vienna, (cited 2011 Aug 22). www.meduniwien.ac.at/Neurologie/gedamb/diag/diag08.htm
«123456»Seite
6 Artikel mit Literatur, Seite 3 von 6

Login

E-Mail

Passwort


Passwort vergessen?

Registrieren

Eingeloggt als

Suchen in